Anavex receives negative CHMP trend vote on blarcamesine MAA; plans re-examination

ANAVEX LIFE SCIENCES CORP.

CHMP issued negative trend vote on MAA for blarcamesine for early Alzheimer's; formal opinion expected December 2025.
Company intends to request re-examination upon formal adoption, including providing relevant biomarker data.
FDA advised Anavex to request a meeting to discuss Alzheimer's clinical trial results.
No change to ongoing FDA review process; company remains in dialogue with regulators.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.